Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age



Status:Recruiting
Healthy:No
Age Range:Any
Updated:5/5/2014
Start Date:January 2014
End Date:January 2018
Contact:Naomi Veney
Email:ClinicalTrialTransparency@astrazeneca.com
Phone:301-398-000

Use our guide to learn which trials are right for you!

This is an observational post-marketing study conducted in children and adults immunized
with Q/LAIV as part of routine clinical practice at Kaiser Permanente Northern California
(NCKP) sites.

Children and adults will be immunized with Q/LAIV as part of routine clinical practice at
Kaiser Permanente Northern California (NCKP) sites. Using existing data on healthcare
utilization, rates of medically attended events (MAEs) of interest will be evaluated in all
eligible Q/LAIV recipients who are vaccinated in the Kaiser Permanente (KP) Northern
California Health Care Plan during the 2013-2014 influenza season. Enrollment must include a
minimum of 10,000 children 2 through 8 years of age; based on previous utilization of
FluMist at NCKP, enrollment is expected to include approximately 80,000 children and adults
2 to 49 years of age.

Inclusion Criteria:

1. . Age 2 through 49 years at the time of vaccination (or index date for unvaccinated
controls)

2. . Membership in the KP Health Care Plan for at least 12 months prior to
vaccination/index date

3. . Continuous enrollment in KP Health Care Plan through 6 months following
vaccination/index date.

Exclusion Criteria:

NONE
We found this trial at
1
site
Oakland, California 94612
?
mi
from
Oakland, CA
Click here to add this to my saved trials